Related Experiment Videos
Concurrent chemoradiotherapy for limited small-cell lung cancer
1Department of Radiation Oncology, Medical University of South Carolina, Charleston, USA.
Oncology (Williston Park, N.Y.)
|October 23, 1997
Summary
Thoracic radiotherapy combined with etoposide is the standard treatment for limited small-cell lung cancer (SCLC). This review details key factors in optimizing thoracic radiotherapy (TRT) for SCLC treatment.
Area of Science:
- Oncology
- Radiation Oncology
- Medical Physics
Background:
- Limited small-cell lung cancer (SCLC) treatment in the US, Canada, and Japan standardly involves thoracic radiotherapy (TRT) and etoposide.
- Platinum agents are often included in combination chemotherapy regimens with etoposide.
- Optimizing TRT delivery is crucial for improving patient outcomes in SCLC.
Purpose of the Study:
- To review and discuss critical factors influencing the efficacy of thoracic radiotherapy (TRT) in limited small-cell lung cancer (SCLC).
- To provide a comprehensive overview of TRT parameters for clinicians treating SCLC.
Main Methods:
- Literature review and discussion of established treatment guidelines and research findings.
- Analysis of key variables in thoracic radiotherapy delivery for SCLC.
Main Results:
- Standard treatment combines TRT with etoposide, often including a platinum agent.
- Key TRT factors discussed include dose, volume, fractionation, timing relative to chemotherapy, and course structure (split vs. continuous).
Conclusions:
- The optimal application of TRT in limited SCLC depends on careful consideration of multiple treatment parameters.
- Further research and clinical consensus on these factors can refine SCLC treatment strategies.